The retrospective design and the treatment period also precluded the collection of data on relevant tumor genomic alterations, such as PIK3CA, AKT, PTEN, and ESR1, which limited our ability to assess the potential association between these tumor mutations and treatment outcomes. This evidence concerns the gene PTEN and neoplasm.